Search Results - "Isnard F"

Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution.

Authors: Isnard, F Guiguet, M Laporte, J Ph et al.

Source: Bone Marrow Transplantation. 5/15/2001, Vol. 27 Issue 10, p1045. 8p.

This result is not displayed to guests.
Login for full access.

Real-time Dynamics Simulation of a Closed-chain Robot Within a Virtual Reality Environment.

Authors: Isnard, F Dodds, G Vallee, C et al.

Source: Proceedings of the Institution of Mechanical Engineers, Part K: Journal of Multi-body Dynamics (Professional Engineering Publishing). 2000, Vol. 214 Issue 4, p219-232. 14p.

Subjects: Dynamics, Robots, Virtual reality

Colpohystérectomie élargie par voie cœlioscopique dans les cancers du col utérin : étude de qualité de vie. À propos de 22 cas

Alternate Title: Quality of life after laparoscopic radical hysterectomy for cervical cancer: Study of 22 cases

Authors: Barranger, E. Isnard, F. Bricou, A. et al.

Source: Gynecologie Obstetrique & Fertilite. Oct2012, Vol. 40 Issue 10, p572-577. 6p.

Impact sur la fonction rénale d’un relais précoce de la formulation conventionnelle de l’amphotéricine B par sa formulation liposomale dans le cadre d’un traitement empirique antifongique (Étude Nephemat)

Alternate Title: Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections

Authors: Isnard, F. Tilleul, P. Laporte, J.-P. et al.

Source: Medecine & Maladies Infectieuses. Apr2008, Vol. 38 Issue 4, p208-214. 7p.

Remission of adult acute lymphocytic leukaemia with Alemtuzumab.

Authors: Laporte, J.P. Isnard, F. Garderet, L. et al.

Source: Leukemia (08876924). Sep2004, Vol. 18 Issue 9, p1557-1558. 2p.

Reply to Piccaluga et al.

Authors: Laporte, J-P Isnard, F Fouillard, L et al.

Source: Leukemia (08876924). Jan2005, Vol. 19 Issue 1, p136-136. 1p.

Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases.

Authors: Smadja, N-V Fruchart, C Isnard, F et al.

Source: Leukemia (08876924). Jun98, Vol. 12 Issue 6, p960-969. 10p.

P0085 : Hepatic encephalopathy: Cerebrospinal fluid metabolomics highlights alteration of multiple metabolic pathways representing new potential therapeutic targets.

Authors: Weiss, N. Isnard, F. Attala, S. et al.

Source: Journal of Hepatology. Apr2015 Supplement 2, Vol. 62, pS332-S332. 1p.

Recombinant human granulocyte-macrophage colony-stimulating factor plus the beam regimen instead of autologous bone marrow transplantation.

Authors: Fouillard, L Gorin, N C Laporte, J P et al.

Source: Lancet. 6/24/1989, Vol. 333 Issue 8652, p1460-1460. 1p.

Subjects: Antineoplastic agents, Bone marrow transplantation, Colony-stimulating factors (Physiology), Granulocyte-colony stimulating factor, Lymphomas, Recombinant proteins, Cytarabine, Benzene derivatives, Carmustine, Melphalan

Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients.

Authors: Ruggeri, A. Roth‐Guepin, G. Battipaglia, G. et al.

Source: Transplant Infectious Disease. Dec2015, Vol. 17 Issue 6, p822-830. 9p.

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study.

Authors: Delannoy, A. Delabesse, E. Lhéritier, V. et al.

Source: Leukemia (08876924). Sep2006, Vol. 20 Issue 9, p1526-1532. 7p. 1 Diagram, 2 Charts, 3 Graphs.

A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.

Authors: Laporte, J. P. H. Yeshurun, M. Fouillard, L. et al.

Source: Leukemia (08876924). Oct2004, Vol. 18 Issue 10, p1717-1721. 5p.

Vesicoovarian Fistula on an Endometriosis Abscessed Cyst.

Authors: Tran, C. Even, M. Carbonnel, M. et al.

Source: Case Reports in Obstetrics & Gynecology. 2014, p1-3. 3p.

Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.

Authors: Scherman, E Malak, S Perot, C et al.

Source: Leukemia (08876924). Apr2012, Vol. 26 Issue 4, p822-824. 3p. 2 Charts.

Progressive multifocal leucoencephalopathy with peripheral demyelinating neuropathy after autologous bone marrow transplantation for acute myeloblastic leukemia (FAB5).

Authors: Coppo, P Laporte, JPh Aoudjhane, M et al.

Source: Bone Marrow Transplantation. 2/15/99, Vol. 23 Issue 4, p401. 3p.

Report of disseminated Mycobacterium haemophilum infection after double cord blood allo-SCT.

Authors: Brissot, E Gomez, A Aline-Fardin, A et al.

Source: Bone Marrow Transplantation. Oct2014, Vol. 49 Issue 10, p1347-1348. 2p.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Authors: Itzykson, R. Thépot, S. Beyne-Rauzy, O. et al.

Source: Leukemia Research. Apr2012, Vol. 36 Issue 4, p397-400. 4p.

Letters to the Editor.

Authors: Henze, TH. Boeer, A. Tebbie, U. et al.

Source: Lancet. 12/12/1987, Vol. 2 Issue 8572, p1391-1408. 18p.

174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)?

Authors: Itzykson, R. Thepot, S. Beyne-Rauzy, O. et al.

Source: Leukemia Research. Jan2011 Supplement 1, Vol. 35, pS68-S68. 1p.